Greenwich LifeSciences, Inc.
GLSIHealthcare|Biotechnology|US
$15.17
+0.52 (+3.55%)
DCF Value
$0.13
Tangible Book / Share
$0.21
Cash / Share
$0.61
Financials
Financial Snapshot
Market Cap
$222.7M
Enterprise Value
$213.8M
Revenue (TTM)
$0.00
Net Income (TTM)
-$21.7M
Cash & Investments
$8.9M
Net Cash
$8.9M
Free Cash Flow (TTM)
-$12.5M
Operating CF (TTM)
-$12.5M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$8.9M
Quarterly Burn
$3.1M
Monthly Burn
$1.0M
Est. Runway
~2.8 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $54.00 | $85.1K | $6.8K | $28.7M | $27.2M | $13.5M | $7.0M | $4.1M | $6.2M | $8.9M | |
| Operating Cash Flow | -$120.8K | -$115.0K | -$293.3K | -$1.2M | -$4.3M | -$6.2M | -$6.5M | -$7.3M | -$9.9M | -$12.5M | |
| Free Cash Flow | -$120.8K | -$115.0K | -$293.3K | -$1.2M | -$4.3M | -$6.2M | -$6.5M | -$7.3M | -$9.9M | -$12.5M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$3.00 | $0.00 | $3.00 | $3.00 | -$3.00 | |
| Financing Cash Flow | -$129.8K | $200.0K | $215.0K | $29.8M | $2.8M | -$7.5M | $0.00 | $4.4M | $12.0M | $18.2M |
R&D Spending
R&D (TTM)
$15.8M
R&D Intensity
—
R&D Growth vs Prior
-8.2%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $1.2M | $1.3M | $2.6M | $1.1M | $3.6M | $6.5M | $7.7M | $15.5M | $17.2M | $15.8M | |
| SG&A | $346.8K | $419.6K | $818.9K | $806.2K | $1.0M | $1.6M | $1.6M | $2.2M | $2.2M | $2.3M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $3.6K | $3.6K | $3.6K | $3.6K | $3.6K | $3.6K | $3.6K | $3.6K | $1.8K | $0.00 | |
| Gross Profit | -$3.6K | -$3.6K | -$3.6K | -$3.6K | -$3.6K | -$3.6K | -$3.6K | -$3.6K | -$1.8K | $0.00 | |
| R&D | $1.2M | $1.3M | $2.6M | $1.1M | $3.6M | $6.5M | $7.7M | $15.5M | $17.2M | $15.8M | |
| SG&A | $346.8K | $419.6K | $818.9K | $806.2K | $1.0M | $1.6M | $1.6M | $2.2M | $2.2M | $2.3M | |
| Operating Income | -$1.6M | -$1.7M | -$3.4M | -$1.9M | -$4.6M | -$8.0M | -$9.3M | -$17.6M | -$19.4M | -$21.9M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$1.6M | -$1.7M | -$3.4M | -$1.9M | -$4.6M | -$7.8M | -$8.9M | -$17.4M | -$19.4M | -$21.7M | |
| Net Income | -$1.6M | -$1.7M | -$3.4M | -$1.9M | -$4.6M | -$7.8M | -$8.9M | -$17.4M | -$19.4M | -$21.7M | |
| EPS (Diluted) | -0.13 | -0.14 | -0.29 | -0.15 | -0.35 | -0.61 | -0.69 | -1.21 | -1.43 | -1.54 | |
| EBITDA | -$1.6M | -$1.7M | -$3.4M | -$1.9M | -$4.6M | -$7.8M | -$8.9M | -$17.4M | -$19.4M | -$21.7M | |
| Shares Out. (M) | 11.74 | 11.97 | 11.74 | 12.70 | 12.94 | 12.91 | 12.85 | 13.01 | 13.53 | 14.62 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $54.00 | $85.1K | $6.8K | $28.7M | $27.2M | $13.5M | $7.0M | $4.1M | $6.2M | $8.9M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $54.00 | $85.1K | $6.8K | $28.7M | $27.2M | $13.5M | $7.0M | $4.1M | $6.2M | $8.9M | |
| Total Assets | $27.1K | $108.5K | $26.7K | $28.7M | $27.2M | $13.5M | $7.0M | $4.1M | $6.2M | $8.9M | |
| Total Current Liabilities | $557.5K | $728.6K | $1.4M | $1.0M | $385.2K | $262.9K | $294.4K | $3.2M | $5.8M | $5.8M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $8.6M | $10.2M | $1.4M | $1.0M | $385.2K | $262.9K | $294.4K | $3.2M | $5.8M | $5.8M | |
| Stockholders' Equity | -$8.5M | -$10.1M | -$1.4M | $27.6M | $26.8M | $13.2M | $6.7M | $908.6K | $353.2K | $3.1M | |
| Retained Earnings | -$22.1M | -$23.8M | -$27.2M | -$29.1M | -$33.6M | -$41.5M | -$50.4M | -$67.8M | -$87.1M | -$96.7M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$120.8K | -$115.0K | -$293.3K | -$1.2M | -$4.3M | -$6.2M | -$6.5M | -$7.3M | -$9.9M | -$12.5M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$3.00 | $0.00 | $3.00 | $3.00 | -$3.00 | |
| Free Cash Flow | -$120.8K | -$115.0K | -$293.3K | -$1.2M | -$4.3M | -$6.2M | -$6.5M | -$7.3M | -$9.9M | -$12.5M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | -$129.8K | $200.0K | $215.0K | $29.8M | $2.8M | -$7.5M | $0.00 | $4.4M | $12.0M | $18.2M | |
| Issuance of Stock | $0.00 | $100.0K | $0.00 | $30.2M | $3.1M | $0.00 | $0.00 | $4.4M | $12.0M | $18.1M | |
| Repurchase of Stock | -$90.0K | $0.00 | $0.00 | $0.00 | $0.00 | -$7.5M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | -$360.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $194.9K | $678.0K | $660.6K | $1.7M | $2.4M | $7.3M | $6.8M | $4.6M | |
| Net Change in Cash | -$250.7K | $85.0K | -$78.3K | $28.7M | -$1.5M | -$13.7M | -$6.5M | -$2.9M | $2.1M | $5.8M |
Dilution Tracker
Shares Outstanding
15M
5-Year Share Growth
+6.5%
Stock Issuance (TTM)
$18.1M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 11.74 | 11.97 | 11.74 | 12.70 | 12.94 | 12.91 | 12.85 | 13.01 | 13.53 | 14.62 | |
| Change vs Prior % | — | 1.9% | -1.9% | 8.2% | 1.9% | -0.2% | -0.5% | 1.3% | 4.0% | 8.0% | |
| Stock Issuance | $0.00 | $100.0K | $0.00 | $30.2M | $3.1M | $0.00 | $0.00 | $4.4M | $12.0M | $18.1M | |
| Stock Repurchase | -$90.0K | $0.00 | $0.00 | $0.00 | $0.00 | -$7.5M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $194.9K | $678.0K | $660.6K | $1.7M | $2.4M | $7.3M | $6.8M | $4.6M |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | 18.4% | 16.7% | 253.6% | -6.7% | -17.0% | -59.2% | -132.7% | -1916.5% | -5480.5% | -793.8% | |
| ROA % | -5805.3% | -1556.6% | -12842.8% | -6.5% | -16.8% | -58.1% | -127.1% | -425.4% | -313.3% | -244.2% | |
| ROIC % | 296.7% | 272.5% | 478.9% | -6.7% | -17.1% | -60.8% | -139.2% | -1941.1% | -5505.9% | -701.6% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | -0.1% | -0.1% | 0.0% | 0.0% | 0.0% | 50.7% | |
| Operating Income | 0.0% | -7.4% | -102.7% | 45.6% | -146.7% | -74.9% | -16.0% | -89.1% | -10.3% | |
| Net Income | 0.0% | -7.4% | -102.7% | 45.6% | -145.4% | -71.2% | -13.6% | -95.8% | -11.2% | |
| EPS (Diluted) | 0.0% | -7.7% | -107.1% | 48.3% | -133.3% | -74.3% | -13.1% | -75.4% | -18.2% | |
| Operating Cash Flow | 0.0% | 4.9% | -155.1% | -293.1% | -272.2% | -44.5% | -4.5% | -12.2% | -36.4% | |
| Free Cash Flow | 0.0% | 4.9% | -155.1% | -293.1% | -272.2% | -44.5% | -4.5% | -12.2% | -36.4% | |
| R&D Expense | 0.0% | 3.8% | 105.2% | -59.4% | 236.6% | 81.9% | 18.9% | 101.1% | 11.2% | |
| SG&A Expense | 0.0% | 21.0% | 95.1% | -1.6% | 28.8% | 50.7% | 4.1% | 32.2% | 3.4% | |
| Total Assets | 0.0% | 300.5% | -75.4% | 107419.8% | -5.1% | -50.5% | -48.1% | -41.5% | 50.9% | |
| Book Value / Share | 0.0% | -16.4% | 86.4% | 1991.5% | -4.7% | -50.6% | -49.0% | -86.6% | -62.6% | |
| Debt | 0.0% | 0.0% | 0.0% | -56.7% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 0.0% | 1.9% | -1.9% | 8.2% | 1.9% | -0.2% | -0.5% | 1.3% | 4.0% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B71.16
10Y Low / Med / High11.74 / 20.17 / 805.09
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.13
Tangible Book / Share
$0.21
Net Current Assets / Share
$0.21
Graham Net-Net
$0.21
Cash / Share
$0.61
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -38.46 | -35.71 | -17.24 | -243.13 | -69.51 | -24.92 | -15.25 | -9.28 | -14.69 | -9.85 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -6.88 | -5.91 | -43.48 | 16.77 | 11.74 | 14.85 | 20.17 | 160.85 | 805.09 | 71.16 | |
| EV/EBITDA | -37.40 | -35.45 | -17.34 | -233.80 | -63.00 | -23.37 | -14.42 | -8.16 | -14.37 | -9.86 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
0.30
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $8.8M | $140.0M |
| Net Income | -$18.7M | -$15.8M | $53.9M |
| EPS | $-1.39 | $-1.17 | $3.98 |
| # Analysts (EPS) | 1 | 1 | 1 |